MARKETS
Markets

Kura Oncology Announces Publication Of Manuscript In Blood, Journal Of The American Society Of Hematology, Detailing Discovery And Preclinical Development Of Ziftomenib

Aug 10, 2026 · 08:36 AM ET· updated 1h ago

– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –– Findings demonstrate differentiated menin binding and activity against

Share
Why It Matters

Kura Oncology shared scientific details about a medicine it's developing, showing it works in lab tests. This kind of published research helps doctors and scientists understand the medicine better, which is a normal step before testing it in real patients.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.